PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements
Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe , Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan
View HTML
Toggle Summary GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting
New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy 69 percent (11 out of 16) of evaluable patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and 56 percent (5 out of 9) of
View HTML
Toggle Summary GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Oct. 26, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Present at Upcoming Investor Conferences
ROCKVILLE, Md. --(BUSINESS WIRE)--Oct. 24, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows: STIFEL 2018 HEALTHCARE CONFERENCE When: November 13, 2018 at 10:15 a.m.
View HTML
Toggle Summary GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
Issued patent expands global patent portfolio for GlycoMimetics’ late-stage drug candidate targeting treatment of broad spectrum of patients with acute myeloid leukemia (AML) ROCKVILLE, Md. --(BUSINESS WIRE)--Aug. 14, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on
View HTML
Toggle Summary GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia
View HTML
Toggle Summary GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
ROCKVILLE, Md. --(BUSINESS WIRE)--Aug. 2, 2018-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018 , and will host a conference call and webcast on Friday, August 10, 2018 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference
ROCKVILLE, Md. --(BUSINESS WIRE)--Jun. 1, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference in New York , on Thursday, June 7, 2018 , at 11:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
Third of three planned trials positions GlycoMimetics to address unmet needs across the AML spectrum ROCKVILLE, Md. --(BUSINESS WIRE)--May 30, 2018-- GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat
View HTML
Toggle Summary GlycoMimetics Reports First Quarter 2018 Results
Based on guidance from the US Food and Drug Administration ( FDA ), announced study design for GlycoMimetics -sponsored Phase 3 trial of candidate GMI-1271 in relapsed/refractory AML Signed study startup agreement with European consortium to prepare to conduct a trial in a second AML indication,
View HTML